+231.3%
NXPI vs MRNA
+537.9%
-306.6%
-53.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.7% | -3.6% | +1.8% | -1.5% |
| 7D | +0.7% | -9.0% | +9.7% | +1.3% |
| 30D | -6.6% | +137.2% | -143.8% | -17.3% |
| 3M | -25.4% | +194.8% | -220.2% | -36.2% |
| 6M | +11.9% | +167.2% | -155.3% | -3.5% |
| YTD | +4.0% | +375.9% | -371.8% | -17.1% |
| 1Y | +1.0% | +465.2% | -464.1% | -21.6% |
| 3Y | +16.3% | +30.4% | -14.0% | +2.1% |
| 5Y | +17.7% | -66.8% | +84.5% | +8.5% |
| All | +231.3% | +537.9% | -306.6% | +198.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling